Complete financial analysis of Think Research Corporation (THKKF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Think Research Corporation, a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- Changyou Alliance Group Limited (1039.HK) Income Statement Analysis – Financial Results
- Guangdong Modern High-tech Fiber Co., Ltd (300876.SZ) Income Statement Analysis – Financial Results
- Fire Rock Holdings Limited (1909.HK) Income Statement Analysis – Financial Results
- Foodbase Group, Inc. (FBGI) Income Statement Analysis – Financial Results
- AJ1G, Inc. (AJYG) Income Statement Analysis – Financial Results
Think Research Corporation (THKKF)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.thinkresearch.com/ca/
About Think Research Corporation
Think Research Corporation, together with its subsidiaries, gathers, develops, and delivers knowledge-based Software-as-a-Service solutions for the health care industry in Canada, the United States, and internationally. The company's products portfolio comprises order sets that structures clinical pathway at the point of care; eReferrals that allows physicians to find and refer specialists directly from EMR systems; VirtualCare, which allows clinicians and allied health professionals to replace in-person appointments with virtual visits; and eForms, a real-time analytics to track resident volumes, signature adherence, and compliance; and COVID-19 clinical tools, as well as clinical support tools for long-term care. Think Research Corporation is based in Toronto, Canada.
| Metric | 2022 | 2021 | 2020 |
|---|---|---|---|
| Revenue | 78.60M | 47.79M | 19.44M |
| Cost of Revenue | 41.22M | 23.39M | 7.51M |
| Gross Profit | 37.39M | 24.40M | 11.93M |
| Gross Profit Ratio | 47.56% | 51.05% | 61.36% |
| Research & Development | 6.78M | 6.57M | 4.45M |
| General & Administrative | 26.96M | 23.01M | 10.68M |
| Selling & Marketing | 9.09M | 8.65M | 3.70M |
| SG&A | 36.05M | 31.66M | 14.38M |
| Other Expenses | 0.00 | 0.00 | 309.00K |
| Operating Expenses | 57.23M | 46.22M | 20.79M |
| Cost & Expenses | 98.45M | 69.61M | 28.30M |
| Interest Income | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.98M | 2.05M | 1.49M |
| Depreciation & Amortization | 14.40M | 7.99M | 1.96M |
| EBITDA | -5.44M | -13.83M | -6.90M |
| EBITDA Ratio | -6.92% | -28.94% | -35.49% |
| Operating Income | -19.84M | -21.82M | -8.86M |
| Operating Income Ratio | -25.24% | -45.65% | -45.55% |
| Total Other Income/Expenses | -4.09M | -6.64M | 305.00K |
| Income Before Tax | -27.91M | -30.51M | -10.04M |
| Income Before Tax Ratio | -35.50% | -63.84% | -51.64% |
| Income Tax Expense | -2.16M | -1.46M | -24.00K |
| Net Income | -25.74M | -29.05M | -10.02M |
| Net Income Ratio | -32.75% | -60.78% | -51.51% |
| EPS | -0.42 | -0.62 | -0.28 |
| EPS Diluted | -0.42 | -0.62 | -0.28 |
| Weighted Avg Shares Out | 60.87M | 46.75M | 35.87M |
| Weighted Avg Shares Out (Dil) | 60.87M | 46.75M | 35.87M |
Think Research Corporation Announces Completion of Plan of Arrangement
Think Research Provides Update on Going Private Transaction
Leading Independent Proxy Advisory Firm ISS Recommends Think Research Corporation Shareholders Approve The Arrangement With Beedie Capital
Think Research's Pharmapod Adopted in University and Colleges Across Canada to Teach Foundations of Medication Safety
Think Research Announces a $5.0 Million Contract Expansion with a Global Pharmaceutical Company
Think Research Enters into Definitive Agreement to be Acquired by Beedie Capital
Beedie Investments Ltd. Amends Convertible Loan Facility with Think Research Corporation
Think Research Announces Agreement for Subsequent Advance Under Existing Convertible Facility
Beedie Investments Ltd. Amends Convertible Loan Facility with Think Research Corporation
Think Research Announces Agreement for Subsequent Advance Under Existing Convertible Facility
Source: https://incomestatements.info
Category: Stock Reports